27799048|t|Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose - volume parameters from deformably-registered plans correlate with late gastrointestinal complications
27799048|a|Derivation of dose - volume correlated with toxicity for multi-modal treatments can be difficult due to the perceived need for voxel-by-voxel dose accumulation. With data available for a single - institution cohort with long follow-up, an investigation was undertaken into rectal dose - volume effects for gastrointestinal toxicities after deformably-registering each phase of a combined external beam radiotherapy (EBRT)/ high-dose-rate (HDR) brachytherapy prostate treatment. One hundred and eighteen patients received EBRT in 23 fractions of 2 Gy and HDR (TG43 algorithm) in 3 fractions of 6.5 Gy. Results for the Late Effects of Normal Tissues - Subjective, Objective, Management and Analytic toxicity assessments were available with a median follow-up of 72 months. The HDR CT was deformably-registered to the EBRT CT. Doses were corrected for dose fractionation. Rectum dose-volume histogram (DVH) parameters were calculated in two ways. (1) Distribution-adding: parameters were calculated after the EBRT dose distribution was 3D-summed with the registered HDR dose distribution. (2) Parameter-adding: the EBRT DVH parameters were added to HDR DVH parameters. Logistic regressions and Mann-Whitney U-tests were used to correlate parameters with late peak toxicity (dichotomised at grade 1 or 2). The 48-80, 40-63 and 49-55 Gy dose regions from distribution-adding were significantly correlated with rectal bleeding, urgency / tenesmus and stool frequency respectively. Additionally, urgency / tenesmus and anorectal pain were associated with the 25-26 Gy and 44-48 Gy dose regions from distribution-adding respectively. Parameter-adding also indicated the low - mid dose region was significantly correlated with stool frequency and proctitis. This study confirms significant dose-histogram effects for gastrointestinal toxicities after including deformable registration to combine phases of EBRT / HDR prostate cancer treatment. The findings from distribution-adding were in most cases consistent with those from parameter-adding. The mid - high dose range and near maximum doses were important for rectal bleeding. The distribution-adding mid - high dose range was also important for stool frequency and urgency / tenesmus. We encourage additional studies in a variety of institutions using a variety of dose accumulation methods with appropriate inter-fraction motion management. NCT NCT00193856. Retrospectively registered 12 September 2005.
27799048	0	35	Prostate external beam radiotherapy	T061	C2367589
27799048	36	44	combined	T080	C0205195
27799048	50	78	high-dose-rate brachytherapy	T061	C0454270
27799048	80	84	dose	T081	C0178602
27799048	87	93	volume	T081	C0449468
27799048	94	104	parameters	T033	C0449381
27799048	110	137	deformably-registered plans	T170	C0002045
27799048	138	147	correlate	T080	C1707520
27799048	153	157	late	T079	C0205087
27799048	158	188	gastrointestinal complications	T046	C0161819
27799048	189	199	Derivation	T080	C1441547
27799048	203	207	dose	T081	C0178602
27799048	210	216	volume	T081	C0449468
27799048	217	227	correlated	T080	C1707520
27799048	233	241	toxicity	T080	C0040539
27799048	246	268	multi-modal treatments	T061	C0087111
27799048	276	285	difficult	T080	C0332218
27799048	316	348	voxel-by-voxel dose accumulation	T059	C0022885
27799048	355	359	data	T078	C1511726
27799048	376	382	single	T081	C0205171
27799048	385	396	institution	T073,T093	C0018704
27799048	397	403	cohort	T098	C0599755
27799048	409	413	long	T080	C0205166
27799048	414	423	follow-up	T058	C1522577
27799048	428	441	investigation	T169	C1292732
27799048	462	468	rectal	T082	C0205052
27799048	469	473	dose	T081	C0178602
27799048	476	482	volume	T081	C0449468
27799048	483	490	effects	T080	C1280500
27799048	495	522	gastrointestinal toxicities	T033	C1142499
27799048	557	562	phase	T079	C0205390
27799048	568	576	combined	T080	C0205195
27799048	577	603	external beam radiotherapy	T061	C2367589
27799048	605	609	EBRT	T061	C2367589
27799048	612	646	high-dose-rate (HDR) brachytherapy	T061	C0454270
27799048	647	665	prostate treatment	T061	C0194790
27799048	692	700	patients	T101	C0030705
27799048	710	714	EBRT	T061	C2367589
27799048	721	730	fractions	T081	C1264633
27799048	736	738	Gy	T081	C0556636
27799048	743	746	HDR	T061	C0454270
27799048	748	762	TG43 algorithm	T170	C0002045
27799048	769	778	fractions	T081	C1264633
27799048	786	788	Gy	T081	C0556636
27799048	790	797	Results	T033	C0683954
27799048	806	906	Late Effects of Normal Tissues - Subjective, Objective, Management and Analytic toxicity assessments	T170	C0450973
27799048	929	935	median	T081	C0876920
27799048	936	945	follow-up	T058	C1522577
27799048	952	958	months	T079	C0439231
27799048	964	967	HDR	T061	C0454270
27799048	968	970	CT	T060	C0040405
27799048	1004	1008	EBRT	T061	C2367589
27799048	1009	1011	CT	T060	C0040405
27799048	1013	1018	Doses	T081	C0178602
27799048	1024	1033	corrected	T080	C0205202
27799048	1038	1056	dose fractionation	T061	C0524811
27799048	1058	1064	Rectum	T023	C0034896
27799048	1065	1086	dose-volume histogram	T170	C3827011
27799048	1088	1091	DVH	T170	C3827011
27799048	1093	1103	parameters	T033	C0449381
27799048	1109	1119	calculated	T052	C1441506
27799048	1137	1156	Distribution-adding	T170	C0025663
27799048	1158	1168	parameters	T033	C0449381
27799048	1174	1184	calculated	T052	C1441506
27799048	1195	1199	EBRT	T061	C2367589
27799048	1200	1204	dose	T081	C0178602
27799048	1205	1217	distribution	T169	C1704711
27799048	1252	1255	HDR	T061	C0454270
27799048	1256	1260	dose	T081	C0178602
27799048	1261	1273	distribution	T169	C1704711
27799048	1279	1295	Parameter-adding	T170	C0025663
27799048	1301	1305	EBRT	T061	C2367589
27799048	1306	1309	DVH	T170	C3827011
27799048	1310	1320	parameters	T033	C0449381
27799048	1326	1331	added	T169	C1524062
27799048	1335	1338	HDR	T061	C0454270
27799048	1339	1342	DVH	T170	C3827011
27799048	1343	1353	parameters	T033	C0449381
27799048	1355	1375	Logistic regressions	T062	C0206031
27799048	1380	1400	Mann-Whitney U-tests	T081	C0242927
27799048	1414	1423	correlate	T080	C1707520
27799048	1424	1434	parameters	T033	C0449381
27799048	1440	1444	late	T079	C0205087
27799048	1445	1449	peak	T080	C0444505
27799048	1450	1458	toxicity	T080	C0040539
27799048	1460	1472	dichotomised	T169	C0332849
27799048	1476	1481	grade	T185	C0441800
27799048	1518	1520	Gy	T081	C0556636
27799048	1521	1525	dose	T081	C0178602
27799048	1526	1533	regions	T082	C0205147
27799048	1539	1558	distribution-adding	T170	C0025663
27799048	1564	1577	significantly	T078	C0750502
27799048	1578	1588	correlated	T080	C1707520
27799048	1594	1609	rectal bleeding	T046	C0267596
27799048	1611	1618	urgency	T047	C0085606
27799048	1621	1629	tenesmus	T184	C0232726
27799048	1634	1649	stool frequency	T033	C0426642
27799048	1664	1676	Additionally	T169	C1524062
27799048	1678	1685	urgency	T047	C0085606
27799048	1688	1696	tenesmus	T184	C0232726
27799048	1701	1715	anorectal pain	T184	C0581362
27799048	1721	1736	associated with	T080	C0332281
27799048	1747	1749	Gy	T081	C0556636
27799048	1760	1762	Gy	T081	C0556636
27799048	1763	1767	dose	T081	C0178602
27799048	1768	1775	regions	T082	C0205147
27799048	1781	1800	distribution-adding	T170	C0025663
27799048	1815	1831	Parameter-adding	T170	C0025663
27799048	1851	1854	low	T080	C0205251
27799048	1857	1860	mid	T082	C0444598
27799048	1861	1865	dose	T081	C0178602
27799048	1866	1872	region	T082	C0205147
27799048	1877	1890	significantly	T078	C0750502
27799048	1891	1901	correlated	T080	C1707520
27799048	1907	1922	stool frequency	T033	C0426642
27799048	1927	1936	proctitis	T047	C0033246
27799048	1943	1948	study	T062	C0681814
27799048	1949	1957	confirms	T033	C0750484
27799048	1958	1969	significant	T078	C0750502
27799048	1970	1984	dose-histogram	T170	C3827011
27799048	1985	1992	effects	T080	C1280500
27799048	1997	2024	gastrointestinal toxicities	T033	C1142499
27799048	2031	2040	including	T169	C0332257
27799048	2041	2064	deformable registration	T170	C0002045
27799048	2068	2075	combine	T080	C0205195
27799048	2076	2082	phases	T079	C0205390
27799048	2086	2090	EBRT	T061	C2367589
27799048	2093	2096	HDR	T061	C0454270
27799048	2097	2112	prostate cancer	T191	C0376358
27799048	2113	2122	treatment	T061	C0087111
27799048	2128	2136	findings	T033	C0243095
27799048	2142	2161	distribution-adding	T170	C0025663
27799048	2175	2180	cases	T169	C0868928
27799048	2181	2196	consistent with	T078	C0332290
27799048	2208	2224	parameter-adding	T170	C0025663
27799048	2230	2233	mid	T082	C0444598
27799048	2236	2240	high	T080	C0205250
27799048	2241	2245	dose	T081	C0178602
27799048	2246	2251	range	T081	C1514721
27799048	2256	2260	near	T080	C1706276
27799048	2261	2268	maximum	T081	C0806909
27799048	2269	2274	doses	T081	C0178602
27799048	2280	2289	important	T080	C3898777
27799048	2294	2309	rectal bleeding	T046	C0267596
27799048	2315	2334	distribution-adding	T170	C0025663
27799048	2335	2338	mid	T082	C0444598
27799048	2341	2345	high	T080	C0205250
27799048	2346	2350	dose	T081	C0178602
27799048	2351	2356	range	T081	C1514721
27799048	2366	2375	important	T080	C3898777
27799048	2380	2395	stool frequency	T033	C0426642
27799048	2400	2407	urgency	T047	C0085606
27799048	2410	2418	tenesmus	T184	C0232726
27799048	2433	2443	additional	T169	C1524062
27799048	2444	2451	studies	T062	C2603343
27799048	2457	2464	variety	T077	C2346866
27799048	2468	2480	institutions	T078	C1272753
27799048	2489	2496	variety	T077	C2346866
27799048	2500	2525	dose accumulation methods	T059	C0022885
27799048	2543	2575	inter-fraction motion management	T058	C1254363